2097600-16-1: Apremilast Impurity 3

2097600-16-1: Apremilast Impurity 3

Apremilast Impurity 3 (CAS NO.-2097600-16-1) IUPAC Name-(S)-N-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)acetamide. Apremilast is an oral phosphodiesterase 4 inhibitor that has an impact on a wide range of inflammatory mediators involved in psoriasis and psoriatic arthritis, this is a novel treatment that focuses on maintaining a balance between pro-inflammatory and anti-inflammatory signals.

Additional information on CAS 2097600-16-1

Catalogue No.

VE008010
CAS No.

2097600-16-1
Molecular Formula

C14H21NO5S
Molecular Weight

315.4 g/mol
Parent drug

Apremilast
IUPAC Name

(S)-N-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)acetamide
Synonyms

(S)-N-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)acetamide
References

Schafer, Peter. “Apremilast Mechanism of Action and Application to Psoriasis and Psoriatic Arthritis.” Biochemical Pharmacology, vol. 83, no. 12, June 2012, pp. 1583–90, https://doi.org/10.1016/j.bcp.2012.01.001.
Status

In-stock

Other products related to apremilast

Request a quote

2097600-16-1: Apremilast Impurity 3

2097600-16-1: Apremilast Impurity 3
Catalogue No.

VE008010
CAS No.

2097600-16-1
Molecular Formula

C14H21NO5S
Molecular Weight

315.4 g/mol
Parent drug

Apremilast
IUPAC Name

(S)-N-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)acetamide
Synonyms

(S)-N-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)acetamide
References

Schafer, Peter. “Apremilast Mechanism of Action and Application to Psoriasis and Psoriatic Arthritis.” Biochemical Pharmacology, vol. 83, no. 12, June 2012, pp. 1583–90, https://doi.org/10.1016/j.bcp.2012.01.001.
Status

In-stock
ListName

Apremilast Impurity 3
Exclusively Supplied by Veeprho

Exclusively Supplied by Veeprho

"*" indicates required fields

Hidden
Products quotation
Name
Url